- Press Release Distribution

Siblings with unique genetic change help scientists progress drug search for type 1 diabetes

Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.

( Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.

Type 1 diabetes (also known as autoimmune diabetes) is a devastating and life-long disease, in which the patient’s immune cells wrongly destroy the insulin producing beta cells in the pancreas. People living with autoimmune diabetes need to test their blood sugar and inject insulin throughout their lives to control their blood sugars and prevent complications.

Autoimmune diabetes with clinical onset in very early childhood is rare and can result from a variety of genetic variants. However, there are many cases of early onset diabetes without known genetic explanation. In addition, some cancer patients treated with a category of immunotherapy known as immune checkpoint inhibitors — which target the same pathway that the mutation was found in — are prone to developing autoimmune diabetes. The reason why only this category of cancer immunotherapy can trigger autoimmune diabetes is not well understood. Like type 1 diabetes, genetic or immunotherapy-associated autoimmune diabetes requires life-long insulin replacement therapy — there is currently no cure.

The new research, published in the Journal of Experimental Medicine, began when researchers studied two siblings who were diagnosed with a rare genetic form of autoimmune diabetes in the first weeks of life. The University of Exeter offers free genetic testing worldwide for babies diagnosed with diabetes before they are nine months old. For most of these babies, this service provides a genetic diagnosis and in around half of these babies, it allows for a change in treatment.

When researchers tested the two siblings in the study, no mutation in any of the known causes was identified. The Exeter team then performed whole genome sequencing to look for previously unknown causes of autoimmune diabetes. Through this sequencing, they found a mutation in the gene encoding PD-L1 in the siblings and realised it could be responsible for their very-early-onset autoimmune diabetes.

Study author Dr Matthew Johnson, from the University of Exeter, UK, said: “PD-L1 has been particularly well studied in animal models because of its crucial function in sending a stop signal to the immune system and its relevance to cancer immunotherapy. But, to our knowledge, nobody has ever found humans with a disease-causing mutation in the gene encoding PD-L1. We searched the globe, looking at all the large-scale datasets that we know of, and we haven’t been able to find another family. These siblings therefore provide us with a unique and incredibly important opportunity to investigate what happens when this gene is disabled in humans.”

The PD-L1 protein is expressed on many different cell types. Its receptor, PD-1, is expressed exclusively on immune cells. When the two proteins bind together it provides a stop signal to the immune system, preventing collateral damage to the bodies tissues and organs.

Researchers from the Rockefeller Institute in New York and King’s College London joined forces with Exeter to study the siblings, with funding from Wellcome, The Leona M. and Harry B. Helmsley Charitable Trust, Diabetes UK, and the US National Institutes for Health. After contacting the family’s clinician in Morocco, the Exeter team visited the siblings where they were living to collect samples and return them to King’s College London, within the crucial ten-hour window for analysis while the immune cells were still alive. The London and New York teams then performed extensive analysis on the siblings’ cells.

Study co-author Dr Masato Ogishi, from the Rockefeller University in New York, said: “We first showed that the mutation completely disabled the function of PD-L1 protein. We then studied the immune system of the siblings to look for immunological abnormalities that could account for their extremely early-onset diabetes. As we previously described another two siblings with PD-1 deficiency, both of whom had multi-organ autoimmunity including autoimmune diabetes and extensive dysregulation in their immune cells, we expected to find severe dysregulation of the immune system in the PD-L1-deficient siblings. To our great surprise, their immune systems looked pretty much normal in almost all aspects throughout the study. Therefore, PD-L1 is certainly indispensable for preventing autoimmune diabetes but is dispensable for many other aspects of human immune system. We think that PD-L2, another ligand of PD-1, albeit less well-studied than PD-L1, may be serving as a back-up system when PD-L1 is not available. This concept needs to be further investigated in the context of artificial blockade for PD-L1 as cancer immunotherapy.”

Study co-author Professor Timothy Tree, from King’s College London, said: “Through studying this one set of siblings – unique in the world to our knowledge – we have found that the PD-L1 gene is essential for avoiding autoimmune diabetes, but is not essential for ‘everyday’ immune function. This leads us to the grand question; ‘what is the role of PD-L1 in our pancreas making it critical for preventing our immune cells destroying our beta cells?’ We know that under certain conditions beta cells express PD-L1. However, certain types of immune cells in the pancreas also express PD-L1. We now need to work out the “communication” between different cell types that is critical for preventing autoimmune diabetes.

“This finding increases our knowledge of how autoimmune forms of diabetes such as type 1 diabetes develop. It opens up a new potential target for treatments that could prevent diabetes in the future. Simultaneously, it gives new knowledge to the cancer immunotherapy field by uniquely providing the results of completely disabling PD-L1 in a person, something you could never manipulate in studies. Reducing PD-L1 is already effective for cancer treatment, and boosting it is now being investigated as a type 1 diabetes treatment – our findings will help accelerate the search for new and better drugs.”

Dr Lucy Chambers, Head of Research Communications at Diabetes UK, said: “Pioneering treatments that alter the behaviour of the immune system to hold off its attack on the pancreas are already advancing type 1 diabetes treatment in the USA, and are awaiting approval here in the UK.

“By zeroing in on the precise role of an important player in the type 1 diabetes immune attack, this exciting discovery could pave the way for treatments that are more effective, more targeted and more transformational for people with or at risk of type 1 diabetes.”

Helmsley Program Officer Ben Williams said: “New drugs often fail in development because scientific discoveries made in animal models don’t translate into humans. As such, drug developers strongly prefer to pursue new drugs where human genetic evidence supports the drug’s target. This study provides such compelling evidence that PD-L1 is a high-priority target to treat T1D, and should be pursued with the ambition of eventually reducing the burden of this difficult to manage disease.”

The paper is entitled ‘Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency’ and is published in the Journal of Experimental Medicine. The research was supported by the National Institute of Health and Care Research (NIHR) Exeter Biomedical Research Centre and The NIHR Exeter Clinical Research Facility.



Four MD Anderson researchers elected AAAS Fellows

Four MD Anderson researchers elected AAAS Fellows
HOUSTON ― In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS). This prestigious distinction stands as one of the highest accolades within the scientific research community. Boyi Gan, Ph.D., Candelaria Gomez-Manzano, M.D., Li Ma, Ph.D., and Sattva Neelapu, M.D., now join this esteemed group of fellows elected by their peers. AAAS’s annual tradition of recognizing leading scientists as fellows dates to 1874. With these newest additions, 68 MD Anderson faculty members ...

Computational biology pioneer Katie Pollard elected as AAAS fellow

Computational biology pioneer Katie Pollard elected as AAAS fellow
SAN FRANCISCO—April 18, 2024—The American Association for the Advancement of Science (AAAS), one of the world’s largest general scientific societies, has elected Gladstone Senior Investigator Katie Pollard, PhD, into its new class of AAAS Fellows, a lifetime honor within the scientific community. AAAS recognized Pollard for her “distinguished contributions to the field of computational biology and bioinformatics, particularly her discovery of Human Accelerated Regions, and development of ...

New “window-of-opportunity” clinical trials explore cutting-edge treatments for cancers of the liver, head and neck

April 18, 2024, TORONTO – A new round of clinical trials supported by the Ontario Institute for Cancer Research (OICR) will harness a unique opportunity to test some of the newest treatment strategies for a range of different cancers. OICR has announced two new clinical trials as part of its Window-of-Opportunity (WOO) Network, which brings together Ontario researchers, clinicians and patients to study the biology of newly diagnosed and recurrent tumours. “‘Window-of-opportunity’ clinical trials take advantage of the two-to-eight-week period between the diagnosis of cancer and the surgery to remove the cancer, at ...

Can bismuth prevent oil leaks – (and save Norwegians billions)?

Can bismuth prevent oil leaks – (and save Norwegians billions)?
Over the next 25 years, as the world shifts away from fossil fuels, the oil and gas wells that have sustained the fossil fuel age will have to be plugged. No big deal, you might think, drilling those wells was the hard part. Plugging them should be no problem. But think again. The Norwegian Continental Shelf, as an example, is punctured by more than 2000 wells. Harald Linga, centre director for SWIPA (see box), a Centre for Research Based Innovation based at SINTEF, Scandinavia’s largest independent research institute, estimates that plugging them using today’s technology will cost upwards of NOK 800 billion – that’s USD 73 billion. And while oil ...

Atmospheric isotopes reveal 4.5 billion years of volcanism on Jupiter’s moon Io

Sulfur and chlorine isotopes in the atmosphere of Jupiter’s moon Io indicate that it has been volcanically active for the entire 4.57 billion-year history of the Solar System, according to a new study. The findings offer new insights into the moon’s history. Io is the most volcanically active body in the Solar System. This extreme level of volcanic activity is the result of tidal heating from friction generated within the moon’s interior as it is pulled between Jupiter and its neighboring moons of Europa and Ganymede. However, how long Io has hosted such extensive ...

An ink for 3D-printing flexible devices without mechanical joints

An ink for 3D-printing flexible devices without mechanical joints
For engineers working on soft robotics or wearable devices, keeping things light is a constant challenge: heavier materials require more energy to move around, and – in the case of wearables or prostheses – cause discomfort. Elastomers are synthetic polymers that can be manufactured with a range of mechanical properties, from stiff to stretchy, making them a popular material for such applications. But manufacturing elastomers that can be shaped into complex 3D structures that go from rigid to rubbery has been unfeasible until now. “Elastomers are usually cast so that their composition cannot be changed in all three dimensions over short length scales. To overcome ...

Association for Chemoreception Sciences (AChemS) 46th Annual Meeting

Media Contact: Dr. Alissa Nolden, Chair - Public Information & Affairs Committee, Bonita Springs, FL— The Association for Chemoreception Sciences (AChemS) stands as a premier organization dedicated to advancing the understanding of chemosensory systems. With a rich history spanning over four decades, AChemS has played a pivotal role in fostering interdisciplinary research and collaboration in the fields of taste, smell, and chemical senses. AChemS provides a platform for scientists, clinicians, and industry members from diverse backgrounds to exchange ideas, present cutting-edge research findings, and address pressing challenges ...

How the Birmingham Drug Discovery Hub created an investment-ready ‘drug library’

A novel approach to drug discovery is enabling University of Birmingham researchers to overcome the ‘valley of death’, where projects fail due to the funding gap between original research and commercial investment.  The approach, detailed in a feature published in the April issue of Drug Discovery Today, has attracted more than £4m in industry funding, grants and industry awards, on the back of just £0.2m investment from the University’s Dynamic Investment Fund (DIF).  The Birmingham Drug Discovery Hub ...

Scientists uncover 95 regions of the genome linked to PTSD

In posttraumatic stress disorder (PTSD), intrusive thoughts, changes in mood, and other symptoms after exposure to trauma can greatly impact a person’s quality of life. About 6 percent of people who experience trauma develop the disorder, but scientists don’t yet understand the neurobiology underlying PTSD.  Now, a new genetic study of more than 1.2 million people has pinpointed 95 loci, or locations in the genome, that are associated with risk of developing PTSD, including 80 that had not been previously identified. The study, from the PTSD working group within the Psychiatric Genomics Consortium (PGC - PTSD) together with Cohen ...

AI tool predicts responses to cancer therapy using information from each cell of the tumor

AI tool predicts responses to cancer therapy using information from each cell of the tumor
With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting. Most of the focus has been on developing genetic sequencing assays or analyses to identify mutations in cancer driver genes, then trying to match treatments that may work against those mutations. But many, if not most, cancer patients do not benefit from these early targeted therapies. In a new study published on April 18, 2024, in the journal Nature Cancer, first author Sanju Sinha, Ph.D., assistant professor in the Cancer Molecular Therapeutics ...


Altering cancer treatment dosing could reduce climate impact, study finds

The secret sex life of coral revealed

New deep learning model is ‘game changer’ for measuring embryo development

Smarter foragers do not forage smarter

A unified account of Darwinism’s varieties

Marketers can manage 'feature creep'

Intermittent fasting shows promise in improving gut health, weight management

Scientists identify gene that could lead to resilient ‘pixie’ corn

Utilizing medical assistants to manage patient portal messages shown to support practice and physician efficiency

Study shows clinic continuity associated with reduced hospital and emergency visits

Recognizing the range of experiences among individuals of Latino, Hispanic, and/or Spanish origin is an essential step toward health equity

study reveals decline in reported medicare outpatient procedures by family physicians amid an aging population

COVID-19 pandemic leads to drop in breast cancer screenings, especially among older and racial minority women

Translating the Surgeon General’s framework on social isolation and loneliness to actionable steps in primary care

Point/counterpoint: Is prediabetes overdiagnosed?

Primary care clinics can help low-income families receive nutritional support benefits

The wall of evidence for continuity of care

Parents of children with serious illness from Somali, Hmong, and Latin American communities desire better communication and support in pediatric health care

Primary care can improve hygienic practices while reducing waste

HKUST researchers enhance performance of eco-friendly cooling applications by developing sustainable strategy to manipulate interfacial heat transfer

Variations in medical assistant to primary care clinician staffing ratios may reflect differences in practice ownership and organizational culture

Better disciplinary structures in schools can help reduce hate speech directed against Asian American students

Bringing back an ancient bird

Wistar research identifies mechanisms for selective multiple sclerosis treatment strategy

Fatherhood’s hidden heart health toll

The importance of integrated therapies on cancer: Silibinin, an old and new molecule

Texas A&M-led team creates first global map of seafloor biodiversity activity

Light therapy increases brain connectivity following injury

Power imbalance in health care reveals impact of race and role on team dynamics and DEI efforts

NRG Oncology appoints new vice-chairs for their patient advocate committee

[] Siblings with unique genetic change help scientists progress drug search for type 1 diabetes
Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.